Powered by

Get Hosting
Neuralink will update us about their progress with a ‘show-and-tell’ on Halloween

Neuralink will update us about their progress with a ‘show-and-tell’ on Halloween

Finally prepared to discuss its work on brain implants, Neuralink is ready to do so. Neuralink will host a “show & tell” progress session on October 31st, according to Elon Musk. He gave no hints as to what to anticipate, but the previous major demonstration featured a chimpanzee playing Pong. A comparable illustration is not at that unexpected.

img via IEEE Spectrum

Quite a bit could depend on this demonstration. The Food and Drug Administration has not indicated how near Neuralink might be to getting approval, and human trials have not yet started. Since the company was created six years ago, the majority of the co-founders have quit. The incident may represent Neuralink’s general state of health when combined with Fortune’s unconfirmed accusations of a dysfunctional workplace culture.

At least the time is ideal. The announcement coincides with allegations that Neuralink has offered to invest in Synchron, a competitor that just completed what looks to be the first endovascular installation of a brain-computer interface in the US. Even though a contract is not guaranteed, a gathering like this can shed light on Synchron’s potential involvement.

Neuralink will update us about their progress with a ‘show-and-tell’ on Halloween

Neuralink will update us about their progress with a ‘show-and-tell’ on Halloween

Finally prepared to discuss its work on brain implants, Neuralink is ready to do so. Neuralink will host a “show & tell” progress session on October 31st, according to Elon Musk. He gave no hints as to what to anticipate, but the previous major demonstration featured a chimpanzee playing Pong. A comparable illustration is not at that unexpected.

img via IEEE Spectrum

Quite a bit could depend on this demonstration. The Food and Drug Administration has not indicated how near Neuralink might be to getting approval, and human trials have not yet started. Since the company was created six years ago, the majority of the co-founders have quit. The incident may represent Neuralink’s general state of health when combined with Fortune’s unconfirmed accusations of a dysfunctional workplace culture.

At least the time is ideal. The announcement coincides with allegations that Neuralink has offered to invest in Synchron, a competitor that just completed what looks to be the first endovascular installation of a brain-computer interface in the US. Even though a contract is not guaranteed, a gathering like this can shed light on Synchron’s potential involvement.